joseph mannello executive profile  biography  bloomberg july    am et personal products company overview of myos rens technology inc snapshotpeople  overviewboard memberscommittees executive profile joseph mannello interim chief executive officer and director myos rens technology incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background mr joseph mannello also known as joe has been interim chief executive officer of myos rens technology inc since september   mr mannello served as a consultant of myos rens technology inc since may  until september  mr mannello has more than  years of experience in fixed income and financial services he served as executive managing director at brean capital llc since march  until may  mr mannello served as head of corporate credit  and executive managing director of gleacher  company inc since march  until march  he served as the head of debt capital markets at broadpoint gleacher securities group inc mr mannello joined gleacher  company in  he served as executive managing director and head of corporate credit division at gleacher  company securities inc mr mannello served as an executive managing director and head of fixed income division of broadpoint securities group inc since january  at bny capital markets mr mannello served as the head of fixed income and managing director from  to  prior to bny capital markets he founded mendham capital mr mannello started his career with printon kane group in  and served as its partner since  and president since  he has been director of myos rens technology inc since december   he served as an independent director of myos rens technology inc since december   mr mannello graduated from rutgers university in read full background corporate headquarters  horsehill roadcedar knolls new jersey united statesphone fax  board members memberships presentinterim chief executive officer and directormyos rens technology inc education unknownother education rutgers the state university of new jersey other affiliations brean capital llcgleacher  company incgleacher  company securities incrutgers the state university of new jersey annual compensation salarytotal annual compensation stocks options restricted stock awardsall other compensation total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationjames robert b quincey president ceo  directorthe cocacola companykmiles d white chairman of the board  chief executive officerabbott laboratoriesmemma walmsley chief executive officer  directorglaxosmithkline plcsiobhan talbot bcomm fcagroup managing director and executive directorglanbia plcmrobert f moran interim chief executive officer and directorgnc holdings inckcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact myos rens technology inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close myos appoints joseph mannello as interim chief executive officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       myos myos appoints joseph mannello as interim chief executive officer tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs cedar knolls njmarketwired  september    highlighted links re muscle health website myos rens technology inc myos rens technology inc myos rens or the company nasdaq myos an emerging biotherapeutics and bionutrition company focused on the discovery development and commercialization of products that improve human muscle health and performance announced the appointment of joseph mannello as its interim chief executive officer effective september   and the election of victor mandel to its board of directors the board the company has the potential to become a truly transformative presence in the bionutrition and biotherapeutics markets mr mannello stated the companys management team and the board are fully committed to achieving this goal and i look forward to bringing my experience leadership and unique perspective to the company as its interim chief executive officer mr mannello has served as a member of the board since december  and as an independent management consultant since may  he previously served as executive managing director and a member of the operating committee of brean capital llc and as executive managing director and as the head of corporate credit of gleacher  company inc mr mannello served as a managing director and the head of the corporate fixed income division of bny capital markets inc and founded and served as the chief executive officer of mendham capital group inc mr mannello received a ba in psychology from rutgers university myos rens also announced the election of victor mandel to the board filling a vacancy resulting from the recent resignation of guiying zhao mr mandel served as a director of myos rens from december  until march  he is the founding partner of criterion capital management llc and has over twentyfive years of experience in investments corporate strategy and corporate governance mr mandel previously served as cochairman of ambac financial group inc from may  through december  and as a director chair of its governance and nominating committee and member of its audit and strategy and risk policy committees from may  until may  additionally he has previously served as a member of the board of directors and on the audit committees of comsys it partners inc now a manpower company broadpoint gleacher securities group inc now gleacher  co inc and xlhealth corp now a united healthcare company he previously served as the chief financial officer of circlecom and served as executive vice president finance and development of snyder communications inc from  to  from  to  mr mandel served as vice president in the investment research department at goldman sachs  co mr mandel holds an mba in finance from the wharton school of business at the university of pennsylvania an ab in computer science from harvard university and is a chartered financial analyst about myos rens technology inc myos rens is an emerging biotherapeutics and bionutrition company focused on the discovery development and commercialization of products that improve muscle health and function essential to the management of sarcopenia cachexia and degenerative muscle diseases myos rens is the owner of fortetropin® the first clinicallyproven all natural myostatinreducing agent myostatin is a naturallyoccurring regulatory protein which inhibits muscle growth and recovery medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass healthy weight management improved energy levels stimulation of muscle healing as well as treating sarcopenia a condition of agerelated loss of muscle mass to discover why myos rens is known as the muscle company™ visit wwwmyosrenscom forwardlooking statements any statements in this release that are not historical facts are forwardlooking statements actual results may differ materially from those projected or implied in any forwardlooking statements such statements involve risks and uncertainties including but not limited to those relating to the successful continued research of fortetropin® and its effects on myostatin inhibition inflammatory cytokine levels and cholesterol levels customer demand for our rē muscle health™ and other products market acceptance of our existing and future products in countries outside of the united states such as canada and china the ability to create new products through research and development growth in our revenue the successful entry into new markets including the age management market the ability to collect our accounts receivable from our distributors our ability to raise capital to fund continuing operations the ability to increase shareholder value the ability to generate revenue and cash flow from sales of fortetropin® and rē muscle health™ products the ability to achieve a sustainable profitable business the effect of economic conditions the ability to protect our intellectual property rights the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products the ability to comply with nasdaqs continuing listing standards competition from other providers and products risks in product development and other factors discussed from time to time in our securities and exchange commission filings we undertake no obligation to update or revise any forwardlooking statement for events or circumstances after the date on which such statement is made except as required by law these statements have not been evaluated by the food and drug administration our products are not intended to diagnose treat cure or prevent any disease company contact joseph mannelloceomyos rens technology incemail contact  investor relations contactmichael briolaceomotion communications incemail contact  read at biospacecom related news myos myos reports positive results from fortetropin clinical study why mylan myl’s ceo remains one of fortunes most powerful women myos myos announces corporate name change to myos rens technology inc how merck  co mrks cio is quietly changing the techstartup world myos myos announces the initial closing of a strategic investment by rens technology inc is there anyone the drug industry hates more than this aids activist myos myos announces election of new directors and appointment of ren ren as global chairman fivefigure salaries big hair pharma  myos myos announces strategic investment by rens technology inc kalobios kbio postshkreli vows maniacal focus on rd and transparency please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • myos   • biotechpharma  personnel                 joseph mannello  myos rens technology inc  zoominfocommyos rens technology inc appoints joseph mannello as interim chief executive officerhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  hrs  minssp  dow  nasdaq myos rens technology inc appoints joseph mannello as interim chief executive officermarketwiredseptember  reblogsharetweetsharecedar knolls njmarketwired  sep     myos rens technology inc myos rens or the company  nasdaq  myos  an emerging biotherapeutics and bionutrition company focused on the discovery development and commercialization of products that improve human muscle health and performance announced the appointment of joseph mannello as its interim chief executive officer effective september   and the election of victor mandel to its board of directors the boardthe company has the potential to become a truly transformative presence in the bionutrition and biotherapeutics markets mr mannello stated the companys management team and the board are fully committed to achieving this goal and i look forward to bringing my experience leadership and unique perspective to the company as its interim chief executive officermr mannello has served as a member of the board since december  and as an independent management consultant since may  he previously served as executive managing director and a member of the operating committee of brean capital llc and as executive managing director and as the head of corporate credit of gleacher  company inc mr mannello served as a managing director and the head of the corporate fixed income division of bny capital markets inc and founded and served as the chief executive officer of mendham capital group inc mr mannello received a ba in psychology from rutgers university myos rens also announced the election of victor mandel to the board filling a vacancy resulting from the recent resignation of guiying zhao mr mandel served as a director of myos rens from december  until march  he is the founding partner of criterion capital management llc and has over twentyfive years of experience in investments corporate strategy and corporate governance mr mandel previously served as cochairman of ambac financial group inc from may  through december  and as a director chair of its governance and nominating committee and member of its audit and strategy and risk policy committees from may  until may  additionally he has previously served as a member of the board of directors and on the audit committees of comsys it partners inc now a manpower company broadpoint gleacher securities group inc now gleacher  co inc and xlhealth corp now a united healthcare company he previously served as the chief financial officer of circlecom and served as executive vice president finance and development of snyder communications inc from  to  from  to  mr mandel served as vice president in the investment research department at goldman sachs  co mr mandel holds an mba in finance from the wharton school of business at the university of pennsylvania an ab in computer science from harvard university and is a chartered financial analystabout myos rens technology inc myos rens is an emerging biotherapeutics and bionutrition company focused on the discovery development and commercialization of products that improve muscle health and function essential to the management of sarcopenia cachexia and degenerative muscle diseases myos rens is the owner of fortetropin® the first clinicallyproven all natural myostatinreducing agent myostatin is a naturallyoccurring regulatory protein which inhibits muscle growth and recovery medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass healthy weight management improved energy levels stimulation of muscle healing as well as treating sarcopenia a condition of agerelated loss of muscle mass to discover why myos rens is known as the muscle company™ visit wwwmyosrenscomforwardlooking statements any statements in this release that are not historical facts are forwardlooking statements actual results may differ materially from those projected or implied in any forwardlooking statements such statements involve risks and uncertainties including but not limited to those relating to the successful continued research of fortetropin® and its effects on myostatin inhibition inflammatory cytokine levels and cholesterol levels customer demand for our rē muscle health™ and other products market acceptance of our existing and future products in countries outside of the united states such as canada and china the ability to create new products through research and development growth in our revenue the successful entry into new markets including the age management market the ability to collect our accounts receivable from our distributors our ability to raise capital to fund continuing operations the ability to increase shareholder value the ability to generate revenue and cash flow from sales of fortetropin® and rē muscle health™ products the ability to achieve a sustainable profitable business the effect of economic conditions the ability to protect our intellectual property rights the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products the ability to comply with nasdaqs continuing listing standards competition from other providers and products risks in product development and other factors discussed from time to time in our securities and exchange commission filings we undertake no obligation to update or revise any forwardlooking statement for events or circumstances after the date on which such statement is made except as required by lawthese statements have not been evaluated by the food and drug administration our products are not intended to diagnose treat cure or prevent any diseasereblogsharetweetsharerecently viewedyour list is emptywhat to read nextphil mickelson trashtalked jordan spieth at the open championship — and phil is going to have to eat his wordsbusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredheres trumps approval rating in every statebusiness insidersenate opens obamacare debate at last but outcome in doubtassociated presseconomists answer are we at full employmentyahoo finance videoa pennycrypto miracle making some americans richagora financialsponsoredstocks rise as the earnings parade marches on and investors wait for the fedyahoo financedonald trump thinks jeff bezos is his biggest threatyahoo financemotorolas moto z force is a smartphone guaranteed not to shatteryahoo financestart earning miles with the best travel cardwise breadsponsoredfix my finances i borrowed from my kyahoo financeformer obama official weighs in on trumps plan to bring back manufacturing jobsyahoo finance videowhy barnes  noble still has value for the right buyeryahoo financesimple athome fix fights almost all skin issuesgundry mdsponsoredtrump sessions only endorsed me because of my crowd sizesbusiness insiderconservative media outlets are sending trump a big warning on jeff sessions — and trump is paying attentionbusiness insiderboy scouts defend inviting trump amid backlash over president’s rambling speechliberaltroll trump goes to the boy scouts and makes everything about him nice huhjoin the conversation  k management team  myos rens technology inc myos our partners contact us menu management team overview analyst coverage news  events press releases ir calendar email alerts videos company information profile management team presentations ir contacts faq financial information financials quarterly results stock data quote charts historical data sec filings all sec filings annual reports quarterly reports section  filings corporate governance board of directors governance docs email alerts tear sheet ir contacts rss news feed joseph mannello director interim ceo joseph mannello has served as a consultant since may  from march  to may  he served as the executive managing director at brean capital llc an independent investment bank and asset management firm where he also served as a member of the firm’s operating committee from march  to march  mr mannello was the head of corporate credit for gleacher  company inc otcglch a publiclytraded investment bank prior to that he was the head of the fixed income division of bny capital markets inc a subsidiary of the bank of new york mellon corp nysebk we believe mr manello’s extensive financial markets background qualifies him to serve on our board of directors joseph dipietro controller joseph dipietro joined myos in september  mr dipietro was most recently the cfo at the harlem school of the arts in new york he graduated st john’s university in  with a bs in accounting he obtained his cpa license while working as an auditor for mcgladrey rsm he has held positions such as vp finance controller and director of financial reporting at a few public companies such as pfizer celgene juno online majesco audible and turtle beach maghsoud dariani science  technology maghsoud dariani has over  years of diverse and progressive management experience in the development and commercialization of products in the pharmaceutical industry mr dariani has a successful record of business management strategic planning acquisition and divestiture project management production management rd management economic evaluations competitor analyses and development and administration of multimillion dollar budgets mr dariani is also an entrepreneurial business leader with a sound grasp of successful business strategies with an excellent foundation in science and engineering and a strong background in product development and commercialization   as president  ceo of semorex inc – a privately held company focused on the discovery and development of novel therapeutics for cancer mr dariani is responsible for overall management of the business and rd as well as securing capital for operations  prior to joining semorex mr dariani was president of focus pharmaceuticals inc where he managed the development and approval of drug products achieving one fda approval and bringing another to the clinical evaluation stage then successfully negotiated the sale of the company in february   prior to focus mr dariani was vice president of the chiral pharmaceutical business unit at celgene corporation  during his twelve years at celgene mr dariani developed and implemented celgene’s manufacturing strategy managed and successfully sold celgene’s chiral intermediates business unit and formulated a strategic plan for leveraging celgene’s expertise in chiral technologies towards the development of chirally pure drug products  mr dariani was responsible for the successful development and fda approval of the chirally pure versions of ritalin which are currently marketed by novartis under the focalin and focalin xr trade names prior to celgene mr dariani held progressively more responsible engineering and development positions at celanese corporation  mr dariani holds a bs degree from the city college of ny and a ms degree from university of massachusetts in chemical engineering  mr dariani is a member of board of directors at semorex inc and mesa therapeutics dominick commesso executive vp of sales and marketing dominick commesso joined myos in february  to spearhead sales and marketing  mr commesso is joining myos after a very successful  year career on wall street as an equity sales trader working on many different institutional size platforms from credit suisse to alex brown he brings his well diversified wall street skill set and deep client relationships to myos corp  mr commesso is a lifetime athlete who played soccer at the division  college level for university of north carolina at charlotte and has coached at the youth level up to high school his passion for health fitness and financial background will help drive global sales and challenge the team every day to be better   neerav dilip padliya phd pmp vice president research alliances neerav dilip padliya phd pmp is vice president research alliances at myos rens technology inc his career success began in  at celgene corporation where he was the principal investigator behind a highly interdisciplinary program focused on mass spectrometrybased proteomic studies of placentaderived populations of stem cells and natural killer cells dr padliya spearheaded collaborations with immunologists and cell biologists that led to the issue of two us patents one pending us patent application and the publication of one journal article as senior author in  dr padliya joined ab sciex a wholly owned operating company of danaher corporation a premier manufacturer of highend mass spectrometry instrumentation used for applications in pharmaceuticals clinical laboratories environmental monitoring and the food and beverage industry prior to joining myos rens technology inc dr padliya worked closely with the north american sales force at ab sciex to perform several winning demonstrations of accurate mass highresolution mass spectrometers that paved the way for new business opportunities with major pharmaceutical and biotechnology accounts dr padliya graduated with a bsc honors chemistry in  from mcmaster university canada and graduated with a phd in analytical chemistry in  from the state university of new york at buffalo usa dr padliya is the author of five peerreviewed publications as first author and an inventor on two us patents and one pending us patent application dr padliya has served as a reviewer for wellreputed journals such as anal chimica acta anal methods integrative biology and molecular biosystems joanne goodford operations facility development manager special projects ms goodford has more than  years of management experience with six years in project operations during contract startup phases on government initiatives in a healthcare setting  her role included office facilities buildouts floor plan development quality assurance establishing processes and workflows recruiting hiring and training of staff  ms goodford also served on several proposal development teams which had a  win rate and included responding to a m contract for the state of georgia with an eye to quality outcomes timely project completion and cost management ms goodford served as project manager for the buildout of myos rens’ corporate offices bringing the project in under budget and under deadline  ms goodford holds a bs from montclair state university alexander tess quality assurance manager mr tess is responsible for implementing and maintaining the effectiveness of the quality system at myos rens technology inc he successfully runs programs that ensure all specifications for products or services are met and monitors progress and compliance through regular inspections mr tess develops standard operating procedures and manages stability studies ensuring compliance with protocols prior to joining myos rens technology inc mr tess worked as a research associate at celgene cellular therapeutics exploring platforms for cellbased therapies in the therapeutic areas of cancer and inflammatory diseases he excelled in establishing methods for differentiation of various cell lines form mesenchymal stem cells as well as characterizing and monitoring cell lines for comprehensive in vitro studies mr tess has a bs in biochemistry from fairleigh dickinson university as well as a bs degree from kazan aviation university in aircraft engineering in addition mr tess has completed pharmaceutical quality assurance and control trainings joseph mannello  myos rens technology inc  email interim ceo myosrenscom login  day free trial joseph mannello myos rens technology inc interim ceo updated on  apr   export email address email not avail  horsehill road cedar knolls nj  email format for myosrenscom direct phone not available type private employees    revenue not available industry biotechhealthcarebiotechdrugs sic code   biological products except diagnostic biography joseph mannello is part of myos rens technology inc an organization which has its main offices in cedar knolls nj joseph serves as the interim ceo at myos rens technology inc if youre searching for myos rens technology inc email addresses you can also find those on their lead profile with the domain myosrenscom along with joseph mannellos linkedin name twitter tweets wiki phone numbers and biographymyos rens technology incs lead profile is categorized under the biotechdrugs industry some possible email formats for joseph mannello are jmannellomyosrenscom josephmannellomyosrenscom josephmyosrenscom and josephmannellomyosrenscom if you sign up for our free trial you will see our emailmyosrenscom addresses similar people joseph m  pro services their recruitment consultant is joseph m their lead profile is categorized under the technology consultingservices industry if youre checking for adronics inc email addresses these are also available on lead with the aiuscom email addresses and possibly joseph ms email adronics inc is based in plano tx you can also get joseph ms linkedin info twitter data phone numbers wiki and biography on their lead profile their contact information is filed under the technology consultingservices category some possible email formats for joseph m are jmaiuscom josephmaiuscom josephaiuscom and josephmaiuscom if you sign up for our free trial you will see our emailaiuscom addresses joseph m  executive have you been looking for contact information like phone numbers and emails on joseph m lead provides data on him which include twitter linkedin url wiki and biography there is also ecolab inc email addresses within the ecolabcom profile so joseph ms email could be included joseph m is part of the ecolab inc which has its main offices in st paul mn currently holds the post of vice president marketing you can find the company data on lead under the personalhousehold products industry some possible email formats for joseph m are jmecolabcom josephmecolabcom josephecolabcom and josephmecolabcom if you sign up for our free trial you will see our emailecolabcom addresses joseph m  pro services joseph m is part of benildest margarets school an organization which has its main offices in st louis park mn joseph serves as the teacher at benildest margarets school if youre searching for benildest margarets school email addresses you can also find those on their lead profile with the domain bsmschoolorg along with joseph ms linkedin name twitter tweets wiki phone numbers and biographybenildest margarets schools lead profile is categorized under the schools industry some possible email formats for joseph m are jmbsmschoolorg josephmbsmschoolorg josephbsmschoolorg and josephmbsmschoolorg if you sign up for our free trial you will see our emailbsmschoolorg addresses people directory  joseph mannello press releases  myos rens technology inc myos our partners contact us menu press releases overview analyst coverage news  events press releases ir calendar email alerts videos company information profile management team presentations ir contacts faq financial information financials quarterly results stock data quote charts historical data sec filings all sec filings annual reports quarterly reports section  filings corporate governance board of directors governance docs email alerts tear sheet ir contacts rss news feed myos rens technology inc appoints joseph mannello as interim chief executive officer download pdf company also announces election of victor mandel to board of directors cedar knolls nj  marketwired    myos rens technology inc myos rens or the company nasdaq myos an emerging biotherapeutics and bionutrition company focused on the discovery development and commercialization of products that improve human muscle health and performance announced the appointment of joseph mannello as its interim chief executive officer effective september   and the election of victor mandel to its board of directors the board the company has the potential to become a truly transformative presence in the bionutrition and biotherapeutics markets mr mannello stated the companys management team and the board are fully committed to achieving this goal and i look forward to bringing my experience leadership and unique perspective to the company as its interim chief executive officer mr mannello has served as a member of the board since december  and as an independent management consultant since may  he previously served as executive managing director and a member of the operating committee of brean capital llc and as executive managing director and as the head of corporate credit of gleacher  company inc mr mannello served as a managing director and the head of the corporate fixed income division of bny capital markets inc and founded and served as the chief executive officer of mendham capital group inc mr mannello received a ba in psychology from rutgers university myos rens also announced the election of victor mandel to the board filling a vacancy resulting from the recent resignation of guiying zhao mr mandel served as a director of myos rens from december  until march  he is the founding partner of criterion capital management llc and has over twentyfive years of experience in investments corporate strategy and corporate governance mr mandel previously served as cochairman of ambac financial group inc from may  through december  and as a director chair of its governance and nominating committee and member of its audit and strategy and risk policy committees from may  until may  additionally he has previously served as a member of the board of directors and on the audit committees of comsys it partners inc now a manpower company broadpoint gleacher securities group inc now gleacher  co inc and xlhealth corp now a united healthcare company he previously served as the chief financial officer of circlecom and served as executive vice president finance and development of snyder communications inc from  to  from  to  mr mandel served as vice president in the investment research department at goldman sachs  co mr mandel holds an mba in finance from the wharton school of business at the university of pennsylvania an ab in computer science from harvard university and is a chartered financial analyst about myos rens technology inc myos rens is an emerging biotherapeutics and bionutrition company focused on the discovery development and commercialization of products that improve muscle health and function essential to the management of sarcopenia cachexia and degenerative muscle diseases myos rens is the owner of fortetropin® the first clinicallyproven all natural myostatinreducing agent myostatin is a naturallyoccurring regulatory protein which inhibits muscle growth and recovery medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass healthy weight management improved energy levels stimulation of muscle healing as well as treating sarcopenia a condition of agerelated loss of muscle mass to discover why myos rens is known as the muscle company™ visit wwwmyosrenscom forwardlooking statements any statements in this release that are not historical facts are forwardlooking statements actual results may differ materially from those projected or implied in any forwardlooking statements such statements involve risks and uncertainties including but not limited to those relating to the successful continued research of fortetropin® and its effects on myostatin inhibition inflammatory cytokine levels and cholesterol levels customer demand for our rē muscle health™ and other products market acceptance of our existing and future products in countries outside of the united states such as canada and china the ability to create new products through research and development growth in our revenue the successful entry into new markets including the age management market the ability to collect our accounts receivable from our distributors our ability to raise capital to fund continuing operations the ability to increase shareholder value the ability to generate revenue and cash flow from sales of fortetropin® and rē muscle health™ products the ability to achieve a sustainable profitable business the effect of economic conditions the ability to protect our intellectual property rights the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products the ability to comply with nasdaqs continuing listing standards competition from other providers and products risks in product development and other factors discussed from time to time in our securities and exchange commission filings we undertake no obligation to update or revise any forwardlooking statement for events or circumstances after the date on which such statement is made except as required by law these statements have not been evaluated by the food and drug administration our products are not intended to diagnose treat cure or prevent any disease company contact joseph mannello ceo myos rens technology inc email contact   investor relations contact michael briola ceo motion communications inc email contact   source myos rens technology inc released september   myos rens technology inc appoints joseph mannello as interim chief executive officer  marketwatch x tweet share this bulletin get news bulletins by email bulletin dow and nasdaq hit alltime highs at wednesday opening bell » investor alert new york markets close in market snapshot winners and losers press release sept    pm edt myos rens technology inc appoints joseph mannello as interim chief executive officer cedar knolls nj sep   marketwired via comtex  company also announces election of victor mandel to board of directors cedar knolls njmarketwired  sep     myos rens technology inc myos rens or the company quoteszigmancomposite myos   an emerging biotherapeutics and bionutrition company focused on the discovery development and commercialization of products that improve human muscle health and performance announced the appointment of joseph mannello as its interim chief executive officer effective september   and the election of victor mandel to its board of directors the board the company has the potential to become a truly transformative presence in the bionutrition and biotherapeutics markets mr mannello stated the companys management team and the board are fully committed to achieving this goal and i look forward to bringing my experience leadership and unique perspective to the company as its interim chief executive officer mr mannello has served as a member of the board since december  and as an independent management consultant since may  he previously served as executive managing director and a member of the operating committee of brean capital llc and as executive managing director and as the head of corporate credit of gleacher  company inc mr mannello served as a managing director and the head of the corporate fixed income division of bny capital markets inc and founded and served as the chief executive officer of mendham capital group inc mr mannello received a ba in psychology from rutgers university  myos rens also announced the election of victor mandel to the board filling a vacancy resulting from the recent resignation of guiying zhao mr mandel served as a director of myos rens from december  until march  he is the founding partner of criterion capital management llc and has over twentyfive years of experience in investments corporate strategy and corporate governance mr mandel previously served as cochairman of ambac financial group inc from may  through december  and as a director chair of its governance and nominating committee and member of its audit and strategy and risk policy committees from may  until may  additionally he has previously served as a member of the board of directors and on the audit committees of comsys it partners inc now a manpower company broadpoint gleacher securities group inc now gleacher  co inc and xlhealth corp now a united healthcare company he previously served as the chief financial officer of circlecom and served as executive vice president finance and development of snyder communications inc from  to  from  to  mr mandel served as vice president in the investment research department at goldman sachs  co mr mandel holds an mba in finance from the wharton school of business at the university of pennsylvania an ab in computer science from harvard university and is a chartered financial analyst about myos rens technology inc myos rens is an emerging biotherapeutics and bionutrition company focused on the discovery development and commercialization of products that improve muscle health and function essential to the management of sarcopenia cachexia and degenerative muscle diseases myos rens is the owner of fortetropin® the first clinicallyproven all natural myostatinreducing agent myostatin is a naturallyoccurring regulatory protein which inhibits muscle growth and recovery medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass healthy weight management improved energy levels stimulation of muscle healing as well as treating sarcopenia a condition of agerelated loss of muscle mass  to discover why myos rens is known as the muscle company™ visit wwwmyosrenscom  forwardlooking statements any statements in this release that are not historical facts are forwardlooking statements actual results may differ materially from those projected or implied in any forwardlooking statements such statements involve risks and uncertainties including but not limited to those relating to the successful continued research of fortetropin® and its effects on myostatin inhibition inflammatory cytokine levels and cholesterol levels customer demand for our rē muscle health™ and other products market acceptance of our existing and future products in countries outside of the united states such as canada and china the ability to create new products through research and development growth in our revenue the successful entry into new markets including the age management market the ability to collect our accounts receivable from our distributors our ability to raise capital to fund continuing operations the ability to increase shareholder value the ability to generate revenue and cash flow from sales of fortetropin® and rē muscle health™ products the ability to achieve a sustainable profitable business the effect of economic conditions the ability to protect our intellectual property rights the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products the ability to comply with nasdaqs continuing listing standards competition from other providers and products risks in product development and other factors discussed from time to time in our securities and exchange commission filings we undertake no obligation to update or revise any forwardlooking statement for events or circumstances after the date on which such statement is made except as required by law these statements have not been evaluated by the food and drug administration our products are not intended to diagnose treat cure or prevent any disease company contact joseph mannello ceo myos rens technology inc email contact   investor relations contact michael briola ceo motion communications inc email contact   �  nasdaq inc all rights reserved quoteszigmancomposite add to watchlist myos myos rens technology inc us  us nasdaq     volume  july   a pe rationa dividend yieldna market cap million rev per employee most popular  commodities corner here’s why oil just scored its biggest oneday rally of   marketwatch first take amd earnings give investors what they wanted — now it must deliver on servers  don’t have a college degree these are the industries with the bestpaid jobs  if you can buy only one stock or etf make it this one  clip from the news hub  gmt christopher nolan’s ‘dunkirk’ virtual reality without the headset find a broker partner center » featured stories seeing america again through new eyes how to dig yourself out of debt move over tesla karma unveils its hybrid sports car the salary you need to afford a home in these  cities why opec will never cut production again log in  am edt july   marketstatecountryus new york open marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest athe allure of ‘damaged’ stocks as tech mania goes wild amcdonalds price target raised to  from  at canaccord genuity aus stocks open higher hit records on round of strong corporate results anasdaq composite index opens higher by  adow jones industrial average advances past intraday record high asp  opens higher by  aboeings stock soars  to record high in morning trade astocks open higher boeing helps push dow to record amcdonalds stock price target raised to  from  at instinet acitigroup stock price target raised to  from  at instinet atexas instruments stock price target raised to  from  at instinet aao smith stock price target raised to  from  at boenning  scattergood acorrectedstate national to be acquired by markel in deal valuing the insurer at nearly  million aford shares are down  after q earnings adiana containerships stock plummets after plans for second reverse stock split in a month ashares of verizon communications are up more than  ashares of dish network are down  premarket ahealthcare fund managers say a spike in drugs and devices will produce big returns adollar steadies as investors await fed’s policy signals aa money manager fights the social pressure for ‘more house’ loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  joseph mannello  myos rens technology inc  email ceo myosrenscom cfo login  day free trial myos rens technology inc myosrenscom  horsehill road cedar knolls nj  phone  fax na type private employees    revenue not available industry biotechhealthcarebiotechdrugs sic code   biological products except diagnostic view employees it intelligence news currently hiring historical trends it intelligence no categories no products found helpful hint the inside view displays a list of technologies and products used internally at a company f i r e w a l l show all analytics audiovideo cdn cms os google analytics google analytics shows you the full customer picture across ads and videos websites and social tools tablets and smartphones that makes it easier to serve your current customers and win new ones youtube youtube is a videosharing website created by three former paypal employees in february  and owned by google since late  on which users can upload view and share videos amazon aws  cloudfront amazon cloudfront is a content delivery web service sign up to see all helpful hint the outside view displays all the technologies and devices which can be seen on the internet news and background news and background company in the news april    new contract customerkansas state universityamountundisclosedlengthundisclosedotherstudy impact of fortetropin on reducing muscle loss in dogs after joint surgery read entire article sign up to see all press events background full company description is available with the free trial name email address department get data neerav padliya title vice president analytical development no email avail research  development export joseph mannello title interim ceo no email avail executive export dominick commesso title evp salesmarketing no email avail sales  marketing export joanne goodford title operations facility development manager special projects no email avail operations export alexander tess title quality assurance manager no email avail technology export joseph dipietro title controller no email avail finance export maghsoud dariani title science  technology no email avail technology export showing  to  of  entries level and organization level and organization historical trends historical trends yearly quarterly weekly quarterly poll question date created current result votes only for logged in user additional info myos rens technology inc is in the biotechdrugs industry their main office can be found in cedar knolls nj and they can be contacted through myos rens technology inc email using the domain myosrenscom format some important contact information like linkedin data phone numbers contacts for cfos etc of which can be found on their lead profile if you sign up for our free trial you will see our emailmyosrenscom addresses company background full company description is available with the free trial ceo reference joseph mannello trying to find joseph mannellos email wiki phone numbers twitter biography and linkedin data you can check out myos rens technology incs profile on lead where you can also get myosrenscom contact information myos rens technology inc is an organization centered in cedar knolls nj which you can find on lead under the biotechdrugs category joseph mannello is their interim ceo some possible email formats for joseph mannello are jmannellomyosrenscom josephmannellomyosrenscom josephmyosrenscom and josephmannellomyosrenscom if you sign up for our free trial you will see our emailmyosrenscom addresses similar companies elusys therapeutics the company profile also contains facebook info phone numbers linkedin accounts cfo contacts and elusys therapeutics email format addresses with the domain of elusyscom elusys therapeutics a biotechdrugs company has its main office in pine brook nj if you sign up for our free trial you will see our emailelusyscom addresses merck  co inc this includes merck  co inc email format addresses with the merckcom domain contacts phone numbers linkedin info cfo employees and facebook profiles merck  co inc is a biotechdrugs business with its headquarters based in kenilworth nj if you sign up for our free trial you will see our emailmerckcom addresses immunomedics inc immunomedics inc a business led by ceo michael garone is part of the biotechdrugs industry immunomedics inc email with the immunomedicscom format you can check their lead profile they hold their main office in morris plains nj and more data like cfo contacts and linkedin data can be found within our profiles if you sign up for our free trial you will see our emailimmunomedicscom addresses company directory  myos rens technology inc microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft joseph mannello  wowcom  web results aol search skip over navigation search the web web images images reference reference we found joseph mannello  searching for joseph mannello ad · wwwspokeocom​joseph mannello searching for joseph mannello get phone  address pics  more social network search white pages directory search public records free people search we found joseph mannello  beenverifiedcom ad · wwwbeenverifiedcom  joseph mannellos phone  address  age  more search free people search search by name search by email best background check social media get contact information we found joseph joseph  peoplelookercom ad · wwwpeoplelookercom​joseph joseph  joseph josephs phone  address  age  more search free uncover potential relatives location history photos  videos email address web results joseph mannello executive profile  biography  bloomberg httpswwwbloombergcomresearchstocksprivatepersonasp mr joseph mannello also known as joe has been interim chief executive officer of myos rens technology inc since september   mr mannello served as a  top  joseph mannello profiles  linkedin httpswwwlinkedincompubdirjosephmannello view the profiles of professionals named joseph mannello on linkedin there are  professionals named joseph mannello who use linkedin to exchange information ideas  joseph mannello greater new york city area on linkedin httpswwwlinkedincominjosephmannellob view joseph mannello’s professional profile on linkedin linkedin is the worlds largest business network helping professionals like joseph mannello discover  joseph mannellos phone number email address  spokeo httpswwwspokeocomjosephmannello  records for joseph mannello find joseph mannellos phone address and email on spokeo the leading online directory who is joseph mannello     bernardsville  waatpcompeoplejosephmannello who is joseph mannello     bernardsville  nj  waatpcomsee also joseph mannello pictures social networks profiles videos weblinks at blogs at  top  joseph mannello profiles in united states  linkedin httpsuslinkedincompubdirjosephmannellousunitedstates view the profiles of professionals named joseph mannello on linkedin there are  professionals named joseph mannello who use linkedin to exchange information ideas  joseph mannello   public records found httpswwwinstantcheckmatecompeoplejosephmannello joseph mannello was found  times in our database matches found in  cities including morrisville pennsylvania summit new jersey  maplewood new jersey myos rens technology inc appoints joseph mannello as  wwwmarketwiredcompressreleasemyosrenstechnologyinc september    et myos rens technology inc appoints joseph mannello as interim chief executive officer  company also announces election of victor mandel  joseph mannello arrest  ulster county httpsjailalertcomarrestrecordsjosephmannellohtml arrested person joseph mannello arrested by ulster county sheriffs office arrest date  myos appoints joseph mannello as interim chief executive  httpswwwbiospacecomnewsmyosappointsjosephmannelloas company contact joseph mannello ceo myos rens technology inc email contact   investor relations contact michael briola ceo motion communications inc we found joseph mannello  searching for joseph mannello ad · wwwspokeocom​joseph mannello searching for joseph mannello get phone  address pics  more social network search white pages directory search public records free people search we found joseph mannello  beenverifiedcom ad · wwwbeenverifiedcom  joseph mannellos phone  address  age  more search free people search search by name search by email best background check social media get contact information we found joseph joseph  peoplelookercom ad · wwwpeoplelookercom​joseph joseph  joseph josephs phone  address  age  more search free uncover potential relatives location history photos  videos email address next search the web  aol inc all rights reservedprivacy   terms of use   about our ads   preferences   contact us   powered by bing™ part of the aol search network